Vreni Schneider - Search Results

Year	Number of Results
2005	2
2006	2
2008	1
2009	1
2010	1
2011	2
2015	1
2024	0

1

Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.

Patsenker E, Stoll M, Millonig G, Agaimy A, Wissniowski T, Schneider V, Mueller S, Brenneisen R, Seitz HK, Ocker M, Stickel F. Patsenker E, et al. Among authors: schneider v. Mol Med. 2011;17(11-12):1285-94. doi: 10.2119/molmed.2011.00149. Epub 2011 Aug 19. Mol Med. 2011. PMID: 21863215 Free PMC article.

2

Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation.

Patsenker E, Sachse P, Chicca A, Gachet MS, Schneider V, Mattsson J, Lanz C, Worni M, de Gottardi A, Semmo M, Hampe J, Schafmayer C, Brenneisen R, Gertsch J, Stickel F, Semmo N. Patsenker E, et al. Among authors: schneider v. Int J Mol Sci. 2015 Mar 27;16(4):7057-76. doi: 10.3390/ijms16047057. Int J Mol Sci. 2015. PMID: 25826533 Free PMC article.

3

Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis.

Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sägesser H, Niedobitek G, Goodman SL, Schuppan D. Patsenker E, et al. Among authors: schneider v. Hepatology. 2009 Nov;50(5):1501-11. doi: 10.1002/hep.23144. Hepatology. 2009. PMID: 19725105 Free PMC article.

4

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.

Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Patsenker E, et al. Among authors: schneider v. J Hepatol. 2011 Aug;55(2):388-98. doi: 10.1016/j.jhep.2010.10.044. Epub 2010 Dec 17. J Hepatol. 2011. PMID: 21168455

5

Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.

Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Neef M, et al. Among authors: schneider v. J Hepatol. 2006 Dec;45(6):786-96. doi: 10.1016/j.jhep.2006.07.030. Epub 2006 Sep 22. J Hepatol. 2006. PMID: 17050028

6

Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.

Biecker E, De Gottardi A, Neef M, Unternährer M, Schneider V, Ledermann M, Sägesser H, Shaw S, Reichen J. Biecker E, et al. Among authors: schneider v. J Pharmacol Exp Ther. 2005 Jun;313(3):952-61. doi: 10.1124/jpet.104.079616. Epub 2005 Mar 15. J Pharmacol Exp Ther. 2005. PMID: 15769867

7

No role of matrixmetalloproteinase-3 genetic promoter polymorphism 1171 as a risk factor for cirrhosis in alcoholic liver disease.

Stickel F, Osterreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, Patsenker E, Schneider V, Kolb A, Friess H, Schuppan D, Puhl G, Seitz HK, Leathart JL, Day CP. Stickel F, et al. Among authors: schneider v. Alcohol Clin Exp Res. 2008 Jun;32(6):959-65. doi: 10.1111/j.1530-0277.2008.00654.x. Epub 2008 Apr 26. Alcohol Clin Exp Res. 2008. PMID: 18445105

8

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J. Neef M, et al. Among authors: schneider v. J Hepatol. 2006 Jan;44(1):167-75. doi: 10.1016/j.jhep.2005.06.015. Epub 2005 Jul 12. J Hepatol. 2006. PMID: 16168515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

8 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year